BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Gene expression profiles to predict recurrence in stage II and III colon cancer

Dataset: Gene expression profiles to predict recurrence in stage II and III colon cancer

Purpose: The present study aimed to develop a classification model to predict recurrence in stage II and III colon cancer, using a...

Registered by ArrayExpress Uploader
View Dataset

Purpose: The present study aimed to develop a classification model to predict recurrence in stage II and III colon cancer, using a previously published 128-gene signature on external and independent material. Experimental Design: Microarray gene expression data from 148 patients (37 Danish patients and 111 patients retrieved from the Gene Expression Omnibus, GSE17536) with stage II and III colon cancer were analyzed using Affymetrix Arrays (Affymetrix, Santa Clara, USA). Based on a known 128-gene signature, a classification model was created with the random forest method, using a training set consisting of stage I colon cancers (with localized disease and a good prognosis) and stage IV colon cancers (with metastasis and a poor prognosis). The classifier were built to predict stage II and III colon cancers as either stage I-like (good prognosis) or stage IV-like (poor prognosis). Results: The 3-year relapse-free survival probability (RFS) of stage III patients predicted to have a good prognosis was 79% compared to 55% of patients with a poor prognosis (P = 0.177, log-rank test). The classification model could not stratify stage II colon cancer. The complete dataset representing: (1) the 37 Danish patients (2) the 111 patients retrieved from Series GSE17536 (re-used data), is linked below as a supplementary file. Tumor samples were obtained from 37 patients with stage II and III colon cancer, who underwent colon resection at the Department of Surgery, Roskilde Hospital, Denmark and the Department of Surgery, Bispebjerg Hospital, Denmark between 2001 and 2008. Purified tumor RNA was reverse-transcribed, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChip Array (Affymetrix, Santa Clara, USA) according to the manufacturers instructions and scanned at the RH Microarray Center, Rigshospitalet, University of Copenhagen.

Species:
human

Samples:
37

Source:
E-GEOD-31595

Updated:
Dec.12, 2014

Registered:
Sep.16, 2014


Factors: (via ArrayExpress)
Sample RELAPSE FREE SURVIVAL TIME TUMOR LOCATION ADJUVANT CHEMOTHERAPY GRADE GENDER AGE TNM-STAGE RECURRENCE NUMBER OF LYMPHNODES RESECTED DEATH HISTOLOGY
GSM78267 47.80 month right colon yes Moderate diff. female 65 III no 17 No adenocarcinoma
GSM782674 48.45 month left colon no moderately diff. male 79 II no 15 No adenocarcinoma
GSM784850 48.53 month left colon no well diff. female 56 II no 14 no adenocarcinoma
GSM78485 5.29 month right colon yes poor diff. female 72 III yes 12 yes adenocarcinoma
GSM784852 28.96 month left colon no well diff. female 79 II yes 22 no adenocarcinoma
GSM784853 41.03 month left colon no moderately diff. female 68 II no 17 no adenocarcinoma
GSM784854 38.73 month right colon no well diff. male 71 II no 30 no adenocarcinoma
GSM784855 36.23 month left colon no moderately diff. female 71 III no 10 no adenocarcinoma
GSM784856 36.10 month left colon no moderately diff. female 68 III no 18 no adenocarcinoma
GSM784857 29.88 month right colon no well diff. female 87 II no 12 yes adenocarcinoma
GSM784858 38.30 month left colon no moderately diff. female 51 II no 16 no adenocarcinoma
GSM784860 36.03 month right colon no moderately diff. male 64 II no 16 no adenocarcinoma
GSM784862 38.33 month right colon no poor diff. male 66 III no 20 no adenocarcinoma
GSM784865 38.92 month right colon yes poor diff. male 62 III no 17 no adenocarcinoma
GSM784867 40.11 month right colon no moderately diff. male 79 II no 14 no adenocarcinoma
GSM78487 36.36 month right colon no well diff. female 65 II no 19 no adenocarcinoma
GSM784873 40.60 month right colon yes not specified female 74 III yes 18 no mucinous adenocarcinoma
GSM784875 36.36 month right colon yes moderately diff. female 62 III no 31 no adenocarcinoma
GSM784878 36.10 month right colon yes poor diff. male 64 III no 21 no adenocarcinoma
GSM78488 20.38 month left colon yes well diff. male 72 III yes 13 yes adenocarcinoma
GSM784884 36.59 month left colon no well diff. female 63 II no 12 no adenocarcinoma
GSM784885 11.67 month right colon no moderately diff. male 88 III yes 12 yes adenocarcinoma
GSM784886 112.11 month right colon no not specified female 77 III no 5 no mucinous adenocarcinoma
GSM784887 26.56 month right colon no moderately diff. male 73 II no not specified yes adenocarcinoma
GSM784888 6.41 month left colon no poor diff. male 80 II yes 4 yes adenocarcinoma
GSM784889 109.84 month left colon no moderately diff. female 80 III no 7 no adenocarcinoma
GSM784890 100.86 month left colon no moderately diff. male 78 II no 16 no adenocarcinoma
GSM78489 42.05 month left colon yes moderately diff. female 70 III yes 10 yes adenocarcinoma
GSM784892 38.14 month right colon no poor diff. male 91 II no 24 yes adenocarcinoma
GSM784893 99.19 month right colon no moderately diff. female 82 II no 15 no adenocarcinoma
GSM784894 33.01 month right colon no moderately diff. female 90 II no not specified yes adenocarcinoma
GSM78490 101.82 month right colon yes moderately diff. female 83 III no 8 no adenocarcinoma
GSM784902 4.60 month right colon no moderately diff. female 81 II yes 12 yes adenocarcinoma
GSM784903 83.11 month right colon no moderately diff. female 89 II no 11 yes adenocarcinoma
GSM784904 96.82 month left colon yes moderately diff. male 69 III no 17 no adenocarcinoma
GSM784905 96.82 month right colon no moderately diff. male 85 II no 15 no adenocarcinoma
GSM784906 43.27 month right colon yes well diff. female 89 III no 10 no adenocarcinoma

Tags

  • cancer
  • colon
  • colon cancer
  • disease
  • external
  • genome

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use